Liver health study for mothers with hepatitis B after childbirth
Part of Digestive system, Infections, Women’s health & pregnancy clinical trials.
This study looks at how often liver enzyme (ALT) levels rise in women with chronic hepatitis B after they give birth, and what factors might predict this. It aims to help guide care after delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 20 and 40 years old
- You have had hepatitis B (HBsAg positive) for more than 6 months
- Your ALT level is 40 U/L or less at the time of enrollment
- You are between 24 weeks of pregnancy and delivery
- If your HBV viral load is high (over 200,000 IU/mL), you must take the antiviral TDF and stop it right after delivery
- If your viral load is lower, you do not need antiviral treatment, but you must follow the study plan and attend follow-ups
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
This study looks at liver problems in pregnant women. If you have elevated liver enzymes or bilirubin, joining may help researchers learn more about how to manage liver health during pregnancy.
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
This study compares two ways to give hepatitis B treatment to pregnant women who have the virus, to see which works better at preventing the baby from getting hepatitis B. If you are in your first or second trimester, this might be an option for you.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hear when a new Elevated Alanine Aminotransferase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.